Wedbush Reiterates Outperform on Janux Therapeutics, Maintains $24 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Janux Therapeutics (NASDAQ:JANX) and maintained a $24 price target.
August 10, 2023 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Janux Therapeutics has received an Outperform rating from Wedbush, with a maintained price target of $24.
The Outperform rating from Wedbush indicates a positive outlook for Janux Therapeutics. The maintained price target of $24 suggests that the analyst believes the stock has potential for growth. This could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100